Aclipse One

Aclipse Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel precision medicines for patients with severe orphan diseases. The company's lead program, M102, is a first-in-class small molecule dual activator of the NRF2 and HSF1 pathways, which are critical for cellular protection against oxidative stress and protein misfolding. Currently focused on Amyotrophic Lateral Sclerosis (ALS), Aclipse is advancing M102 through Phase 1 clinical development with support from major patient advocacy groups and international research collaborations. Beyond ALS, the company is exploring the potential of its therapeutic candidates in other neurodegenerative and gastrointestinal orphan indications.